Shares of Synthetic Biologics Inc. (SYN) were up over 34% in extended trading on Tuesday, following positive data from a second phase II trial of SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).
Forex – financial instrument.Forex news
Shares of Synthetic Biologics Inc. (SYN) were up over 34% in extended trading on Tuesday, following positive data from a second phase II trial of SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).